Lakefront Biotherapeutics (LKFT) vs Arcus Biosciences (RCUS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Lakefront Biotherapeutics (LKFT) has outperformed Arcus Biosciences (RCUS) over the past year, gaining 8.6% versus a loss of 29.2%. Over five years, LKFT leads with a -31.8% price change compared with -66.3% for RCUS. Arcus Biosciences is the larger company by market cap ($2.25 billion vs $2.18 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LKFT | RCUS |
|---|---|---|
| Share price | $33.31 | $15.62 |
| Market cap | $2.18B | $2.25B |
| 1-day change | -0.24% | -1.01% |
| YTD return | +1.87% | -34.45% |
| 1-year return | +8.64% | -29.16% |
| 5-year return | -31.80% | -66.31% |
| P/E ratio (TTM) | 2.39 | — |
| EPS (TTM) | $13.94 | $-3.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $247.00M |
| Revenue growth (YoY) | — | -4.26% |
| Net income (latest FY) | — | $-353.00M |
| Operating margin | — | -156.28% |
| Net margin | — | -142.91% |
| 52-week high | $36.24 | $31.74 |
| 52-week low | $25.68 | $15.56 |
| Distance from 52-week high | -8.08% | -50.78% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | -7.39% | +162.48% |
| Average volume | 280.49K | 1.85M |
| Shares outstanding | 65.48M | 143.99M |
| Employees | 196 | 601 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LKFT has outperformed RCUS by 37.8 percentage points over the past year.
About Lakefront Biotherapeutics
LKFT stock →Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
Health Care · Biotechnology: Pharmaceutical Preparations · 196 employees
About Arcus Biosciences
RCUS stock →Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.
Health Care · Biotechnology: Pharmaceutical Preparations · 601 employees
LKFT vs RCUS FAQ
Which is bigger, Lakefront Biotherapeutics or Arcus Biosciences?
Arcus Biosciences (RCUS) is larger, with a market capitalization of $2.25B compared with $2.18B for Lakefront Biotherapeutics (LKFT).
Which stock has performed better over the past year, LKFT or RCUS?
LKFT returned +8.64% over the past 12 months, compared with -29.16% for RCUS (price return, excluding dividends). Past performance does not predict future results.
Are Lakefront Biotherapeutics and Arcus Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.